Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions

Seminars in Interventional Radiology

Volumn 27, Issue 4, 2010, Pages 412-421

  Stangl, P Anondo ^a   Lewis, Sara ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

anticoagulation; Glycoprotein IIb IIIa antagonist; peripheral vascular intervention; platelet aggregation; thromboembolism

Indexed keywords

EID: 78349260880     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0030-1267856     Document Type: Review

References (50)

1. Coller B S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995 92 (9) 2373-2380
2. Hardisty R M., Dormandy K M., Hutton R A. Thrombasthenia: studies on three cases. Br J Haematol 1964 10 371-387
3. Caen J P., Castaldi P A., Leclerc J C. et al. Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann's thrombasthenia (report of fifteen patients). Am J Med 1966 41 4-21
4. Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? J Vasc Interv Radiol 2002 13 (3) 229-246
5. Awtry E H., Loscalzo J. Aspirin. Circulation 2000 101 (10) 1206-1218
6. Breddin H K. Antiplatelet agents in cardiovascular and cerebrovascular diseases. Clin Appl Thromb Hemost 1998 4 87-95
7. Meadows T A., Bhatt D L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007 100 (9) 1261-1275
8. Furman M I., Frelinger A L. III, Michelson A D. GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis 2004 18 (1) 11-17
9. Gold H K., Garabedian H D., Dinsmore R E. et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997 95 (7) 1755-1759
10. Coller B S. Platelets and thrombolytic therapy. N Engl J Med 1990 322 (1) 33-42
11. Smith S C. Jr, Feldman T E., Hirshfeld J W. Jr et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006 113 (7) e166-e286
12. King S B. III, Smith S C. Jr, Hirshfeld J W. Jr et al, 2005 WRITING COMMITTEE MEMBERS. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Writing on Behalf of the 2005 Writing Committee. Circulation 2008 117 (2) 261-295
13. Cohen M. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009 74 (4) 579-597
14. Topol E J., Califf R M., Weisman H F. et al., The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994 343 (8902) 881-886
15. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 336 (24) 1689-1696
16. Tepe G, Schott U, Erley C M., Albes J, Claussen C D., Duda S H. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR Am J Roentgenol 1999 172 (5) 1343-1346
17. Duda S H., Tepe G, Luz O et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alonea randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis. Radiology 2001 221 (3) 689-696
18. Drescher P, McGuckin J, Rilling W S., Crain M R. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab. AJR Am J Roentgenol 2003 180 (5) 1385-1391
19. Ouriel K, Castaneda F, McNamara T et al. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Interv Radiol 2004 15 (3) 229-238
20. Tepe G, Hopfenzitz C, Dietz K et al. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysisAPART trial. Radiology 2006 239 (3) 892-900
21. Schweizer J, Kirch W, Koch R, Mller A, Hellner G, Forkmann L. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000 51 (11) 913-923
22. McNamara T O. Combination of ReoPro and Retevase in thrombolysis of peripheral arterial occlusion: preliminary results. (abstract) J Vasc Interv Radiol 2001 12 (suppl) S123
23. Drescher P, McGuckin J, Rilling W S., Crain M R. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab. AJR Am J Roentgenol 2003 May 180 (5) 1385-1391
24. Yoon H C., Miller F J. Jr. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions. AJR Am J Roentgenol 2002 178 (3) 617-622
25. Burkart D J., Borsa J J., Anthony J P., Thurlo S R. Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study. J Vasc Interv Radiol 2003 14 (6) 729-733
26. Schweizer J, Kirch W, Koch R, Mller A, Hellner G, Forkmann L. Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis. Angiology 2003 54 (2) 155-161
27. Duda S H., Tepe G, Bala M et al. Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion. Pharmacoeconomics 2002 20 (3) 203-213
28. Drffler-Melly J, Mahler F, Do D D., Triller J, Baumgartner I. Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience. Radiology 2005 237 (3) 1103-1109
29. Ansel G M., Silver M J., Botti C F. Jr et al. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial. Catheter Cardiovasc Interv 2006 67 (2) 288-297
30. Feiring A J., Wesolowski A A., Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J Am Coll Cardiol 2004 44 (12) 2307-2314
31. Scarborough R M., Kleiman N S., Phillips D R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999 100 (4) 437-444
32. Kereiakes D J., Runyon J P., Broderick T M., Shimshak T M. IIb's are not IIb's. Am J Cardiol 2000 85 (8A, 8A) 23C-31C
33. Mascelli M A., Lance E T., Damaraju L, Wagner C L., Weisman H F., Jordan R E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998 97 (17) 1680-1688
34. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000 356 (9247) 2037-2044
35. Schrr K, Weber A A. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003 15 (2) 71-80
36. Tcheng J E. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000 139 (2 Pt 2) S38-S45
37. Memon M A., Blankenship J C., Wood G C., Frey C M., Menapace F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000 109 (3) 213-217
38. Kleiman N S., Tcheng J E. Safety issues surrounding use of platelet GPIIb/IIIa antagonists: reversibility and readministration. Eur Heart J 1999 1 (suppl E) E36-E42
39. Nurden A T., Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999 19 (12) 2835-2840
40. Bougie D W., Wilker P R., Wuitschick E D. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002 100 (6) 2071-2076
41. Said S M., Hahn J, Schleyer E et al. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol 2007 96 (2) 61-69
42. Keeley E C. Abciximab following clopidogrel reduces post-PCI complications in patients with acute coronary syndromes. Nat Clin Pract Cardiovasc Med 2006 3 (12) 650-651
43. Ellis S G., Tendera M, de Belder M A. et al, FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 358 (21) 2205-2217
44. Marmur J D., Mitre C A., Barnathan E, Cavusoglu E. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am Heart J 2006 152 (5) 876-881
45. Fischell T A., Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006 18 (10) 487-491
46. Marmur J D., Poludasu S, Agarwal A et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006 18 (11) 521-526
47. Kini A S., Chen V HT, Krishnan P et al. Bolus-only versus bolus+infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2008 156 (3) 513-519
48. Fung A Y., Saw J, Starovoytov A et al. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009 53 (10) 837-845
49. Valgimigli M, Bolognese L, Anselmi M et al. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial. Am Heart J 2007 154 39-45
50. Teirstein P S., Kao J, Watkins M et al. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol 2005 96 (4) 500-505